High-content multiplexed tissue imaging and quantification for cancer drug discovery.

Autor: Falcon BL; Eli Lilly and Company, Department of Cancer Angiogenesis, Lilly Corporate Center, Indianapolis, IN 46285, USA., Stewart J, Ezell S, Hanson J, Wijsman J, Ye X, Westin E, Donoho G, Credille K, Uhlik MT
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2013 Jun; Vol. 18 (11-12), pp. 510-22. Date of Electronic Publication: 2012 Sep 01.
DOI: 10.1016/j.drudis.2012.08.008
Abstrakt: Targeting multiple hallmarks of cancer with drug combinations may provide unique opportunities for cancer therapeutics; however, phenotypic quantification is necessary to understand in vivo mechanisms of action of each drug alone or in combination. Immunohistochemistry (IHC) can quantify phenotypic changes, but traditional methods are not amenable for high-throughput drug discovery. In this article, we describe a high-content method to quantify changes in tumor angiogenesis, vascular normalization, hypoxia, tumor cell proliferation, and apoptosis using IHC. This method to quantify tumor model phenotypes can be useful for cancer drug discovery by increasing the understanding of: (i) tumor models used in efficacy studies, (ii) changes occurring during the growth of the tumor, and (iii) novel mechanisms of actions of cancer therapeutics.
(Copyright © 2012 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: